| Literature DB >> 31440078 |
T Paolucci1, R G Bellomo2, M A Centra1, N Giannandrea1, L Pezzi1, R Saggini1.
Abstract
BACKGROUND: Mesotherapy can be included as an ancillary treatment in the management of localized pain in rehabilitation, but there are no definitive treatment protocols for this approach.Entities:
Keywords: intradermal injection; mesotherapy; musculoskeletal; pain; rehabilitation
Year: 2019 PMID: 31440078 PMCID: PMC6679691 DOI: 10.2147/JPR.S209610
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1Flowchart of study identification and selection.
Abbreviation: RCT, randomized controlled trial.
Summary of articles
| Authors | Diagnosis | N (M/F) | Study | N e/c | Intervention | Outcome parameters | Period of follow-up | PEDro Score |
|---|---|---|---|---|---|---|---|---|
| Chen et al (2018) | OA | 50 (7M/43F) | NCT | 26/24 | Mesotharapy (lidocaine, piroxicam, calcitonin (acute phase) or procaine, organic silica (chronic phase) vs oral diclofenac | WOMAC for pain, stiffness, and function | T0: baseline | 5/10 |
| Genc-Koyucu et al (2018) | LBP* | 168 (168F) | RCT | 84/84 | Mesotherapy with sterile water vs dry mesotherapy | VAS for pain; a satisfaction scale; IBFAT for infant breastfeeding | T0: baseline | 8/10 |
| Paolucci et al (2016) | CNP | 42 (18M/24F) | RS | 22/20 | Mesotherapy with local anesthetic lidocaine hydrochloride vs dry mesotherapy | VAS for pain; NDI for perceived pain and disability; VRS for pain; SF-12 for quality of life | T0: baseline | 7/10 |
| Yang et al (2018) | ANP | 36 (15M/21F) | RCT | 18/18 | Mesotherapy with local anesthetic and steroid vs oral ibuprofen | VAS for pain; NDI for perceived pain and disability; PGIC for patient’s belief | T0: baseline | 8/10 |
| Saggini et al (2015) | OA | 117 (59M/58F) | RCT | 60/57 | Mesotherapy with sodium diclofenac vs oral sodium diclofenac | VAS for pain; KOOS for knee function | T0: baseline | 8/10 |
| Ferrara et al (2017) | CSP | 217 (55M/162F) | RS | 110/107 | Mesotherapy with drug cocktail (normal saline solution, lidocaine hydrochloride, lysine acetylsalicylate) vs mesotherapy with normal saline solution | VAS and McGill for pain | T0: baseline | 7/10 |
| Cui et al (2016) | ALBP | 68 (27M/41F) | RCT | 34/34 | Mesotherapy with sterile water vs mesotherapy with isotonic saline | VAS for pain; Patient-specific functional scale for functional status; Global rating of change for patients’ global impression | T0: baseline | 8/10 |
Abbreviations: WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS, visual analog scale; IBFAT, Infant Breastfeeding Assessment Tool; NDI, Neck Disability Index; VRS, Verbal Rating Scale; SF-12, Short Form-12 Health Survey; PGIC, Patient Global Impression of Change; KOOS, Knee Injury and Osteoarthritis Outcome Score; OA, osteoarthritis; LBP, low back pain; CNP, chronic neck pain; ANP, acute neck pain; CSP, chronic spinal pain; ALBP, acute low back pain; N, number of samples; E, experimental; C, control; M, male; F, female; LBP*, low back pain in labor; RCT, randomized controlled trial; NCT, nonrandomized controlled trial; RS, retrospective study.
Number of mesotherapy sessions
| Study | Disease | Number of Sessions |
|---|---|---|
| Chen et al | Osteoarthritis of the knee | 3 sessions on D1, D8, and D15 and on request thereafter (group E); twice per day for the first 3 months and then on request (group C); |
| Genc et al | Women with low back pain in labor | One session (4 injections for every patient) |
| Paolucci et al | Neck pain | 3 sessions (1 time per week) (for both groups) |
| Yang et al | Nonspecific neck pain | 1 session (group E); 3 daily administrations (group C) |
| Saggini et al | Pes anserine in patients with symptomatic osteoarthritis | 9 sessions of mesotherapy, 3 times per week (group E); 21 oral administrations of oral diclofenac, once every day (group C) |
| Ferrara et al | Chronic spinal pain | 5 sessions of mesotherapy, 1 per week (for both groups) |
| Cui et al | Acute low back pain | 1 session of intracutaneous injection (for both groups); an intramuscular injection of parecoxib sodium if needed for additional treatment |
Abbreviations: E, experimental; C, control.